Andrew Singer joined Wells Fargo Securities as managing director focused on the biopharmaceutical industry. He will be based in San Francisco.

“We are excited to have Andy join us, as he brings a unique perspective that will be impactful to our clients,” said John Hudson, co-head of Investment Banking Coverage at Wells Fargo Securities. “As a veteran investment banker and former chief financial officer, he will complement and enhance our existing biopharmaceutical coverage team. His addition reaffirms our commitment to this sector, which is one of the fastest growing on our investment banking platform.”

Singer previously served as executive vice president, finance and administration, and chief financial officer at Epizyme, a biopharmaceutical company focused on creating novel therapeutics for patients with genetically defined cancers. Prior to that, he was a managing director in the Life Sciences Group at RBC Capital Markets. He also held various positions at Robertson, Stephens, The Shansby Group and The Blackstone Group.